c ebpβ-lip drug Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer | Journal of Experimental & Clinical Cancer Research C/EBP beta Antibody | Cell
C EBP beta Antibody Cell Signaling Technology Natural Products with Antitumor Potential Targeting the MYB C EBP p300 Transcription Module Alignment of CEBPb isoforms LAP*, LAP, and LIP created and annotated Download Scientific Diagram C EBP sustains the oncogenic program of AML cells by cooperating with MYB and co activator p300 in a transcriptional module Experimental Hematology C EBP beta (LAP) Antibody Cell Signaling Technology
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17


